Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxabact in primary hyperoxaluria
NL-OMON31288Phase 3Not yet recruiting
- Sponsor
- OxThera AB
- Start
- Sep 2007
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Primary hyperoxaluria (PH) comparing Oxabact with Placebo (2 arms). Primary endpoint: Percentage change in urinary oxalate from baseline to Week 24. Planned start Sep 2007; status: not yet recruiting.
02
Drugs
oxalobacter formigenes
03
Conditions
Primary hyperoxaluria (PH)
Beyond the preview
Go deeper on NL-OMON31288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31288.